Canaccord Genuity Maintains a 'Buy' on Valeant Pharmaceuticals (VRX); Q1 Preview: Focusing on The Task at Hand

Canaccord Genuity maintains a 'Buy' on Valeant Pharmaceuticals (NYSE: VRX), PT $54.

Canaccord analyst says, "Valeant will report Q1 results on Monday, May 9 and will hold a conference call at 10am ET to discuss the results. Now that the bid for Cephalon is no longer the focus, we expect that investors will turn their attention to synergies from the Biovail merger. We believe that the market expects Valeant will continue to be acquisitive going forward, and management must now demonstrate that it is capable of wringing out value by keeping synergies from its largest transaction on track."

For more ratings news on Valeant Pharmaceuticals click here and for the rating history of Valeant Pharmaceuticals click here.

Shares of Valeant Pharmaceuticals closed at $49.10 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• UBS Downgrades Vicinity Centers (VCX:AU) (CNRAF) to Neutral
• RBC Capital Downgrades Super Retail Group Ltd. (SUL:AU) to Sector Perform
• Barclays Downgrades Renault SA (RNO:FP) (RNSDF) to Equalweight